RETA / IGF-1 LR3Interpret the evidence
Why a body scan leaves a separate question about muscle function
2 numbered sourcesSource years 1997, 2025
Peptides are short amino-acid chains connected by peptide bonds. They can act as signals by interacting with receptors. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered form of insulin-like growth factor 1. An older retatrutide substudy used body scans to distinguish changes in fat from changes in lean tissue. Its design helps explain what evidence is missing for the named pair. [1, 2]
In that phase 2 substudy, adults with type 2 diabetes were assigned to retatrutide, dulaglutide or placebo. The main scan measure examined percentage change in total fat mass at 36 weeks. The researchers used dual-energy X-ray absorptiometry, or DXA. This technique estimates fat mass, lean soft tissue and bone-related measures. It gives a more detailed account of body composition than a scale alone. [1]
Lean mass includes more than the muscles that produce movement. It also includes water and other tissues. A change in lean mass and a change in a strength test can therefore tell different stories. The older IGF-1 LR3 literature includes experiments in animal models, such as one in pigs that measured growth and circulating hormones. Those outcomes cannot supply the missing strength measurement in adults receiving retatrutide. [1, 2]
The substudy tested retatrutide under a defined protocol, and its scans belong to those study groups. It contained no comparison with IGF-1 LR3 added. Determining whether the named pair affected muscle strength would require a study that measures function and assigns the relevant interventions. A scan can be one part of that design alongside measurements that capture what people are able to do. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.T. Coskun et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology (publication 2025-06-30). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
